



# Synuclein- $\alpha$ (phospho Ser129) Polyclonal Antibody

<b>Catalog No</b>	YP-Ab-12635
<b>Isotype</b>	IgG
<b>Reactivity</b>	Human;Mouse;Rat
<b>Applications</b>	WB;IHC;IF;ELISA
<b>Gene Name</b>	SNCA
<b>Protein Name</b>	Alpha-synuclein
<b>Immunogen</b>	The antiserum was produced against synthesized peptide derived from human Synuclein around the phosphorylation site of Ser129. AA range:91-140
<b>Specificity</b>	Phospho-Synuclein- $\alpha$ (S129) Polyclonal Antibody detects endogenous levels of Synuclein- $\alpha$ protein only when phosphorylated at S129.
<b>Formulation</b>	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
<b>Source</b>	Polyclonal, Rabbit,IgG
<b>Purification</b>	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
<b>Dilution</b>	WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/5000.. IF 1:50-200
<b>Concentration</b>	1 mg/ml
<b>Purity</b>	$\geq 90\%$
<b>Storage Stability</b>	-20°C/1 year
<b>Synonyms</b>	SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
<b>Observed Band</b>	15kD
<b>Cell Pathway</b>	Cytoplasm . Membrane . Nucleus . Cell junction, synapse . Secreted . Cell projection, axon . Membrane-bound in dopaminergic neurons (PubMed:15282274). Expressed and colocalized with SEPTIN4 in dopaminergic axon terminals, especially at the varicosities (By similarity). .
<b>Tissue Specificity</b>	Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain.
<b>Function</b>	alternative products:Additional isoforms seem to exist,disease:Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.,disease:Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages an



**Background**

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2016],


**matters needing attention**

Avoid repeated freezing and thawing!


**Usage suggestions**

This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

**Products Images**



Immunohistochemistry analysis of paraffin-embedded human brain, using Synuclein (Phospho-Ser129) Antibody. The picture on the right is blocked with the phospho peptide.



Western blot analysis of lysates from mouse brain, using Synuclein (Phospho-Ser129) Antibody. The lane on the right is blocked with the phospho peptide.